Craniospinal irradiation with concomitant and adjuvant temozolomide—a feasibility assessment of toxicity in patients with glioblastoma with a PNET component

详细信息    查看全文

• 作者：Ben O'Leary ; Henry C. Mandeville ; Naomi Fersht…
• 关键词：Craniospinal irradiation ; Temozolomide ; Glioblastoma ; PNET ; GBM ; PNET
• 刊名：Journal of Neuro-Oncology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：127
• 期：2
• 页码：295-302
• 全文大小：368 KB
• 参考文献：1.Burger PC, Vogel FS, Green SB, Strike TA (1985) Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications. Cancer 56(5):1106–1111CrossRef PubMed
  2.Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRef PubMed
  3.Brandes AA, Tosoni A, Franceschi E et al (2009) Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 27(8):1275–1279CrossRef PubMed
  4.Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003CrossRef PubMed
  5.Hegi ME, Liu L, Herman JG et al (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189–4199CrossRef PubMed
  6.Perry A, Miller CR, Gujrati M et al (2009) Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol 19(1):81–90CrossRef PubMed
  7.Packer RJ, Sutton LN, Elterman R et al (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81(5):690–698CrossRef PubMed
  8.Packer RJ, Gajjar A, Vezina G et al (2006) Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24(25):4202–4208CrossRef PubMed
  9.Jakacki RI, Burger PC, Zhou T et al (2012) Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a children’s oncology group phase I/II study. J Clin Oncol 30(21):2648–2653CrossRef PubMed PubMedCentral
  10.Gajjar A, Chintagumpala M, Ashley D et al (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7(10):813–820CrossRef PubMed
  11.Tait DM, Thornton-Jones H, Bloom HJG, Lemerle J, Morris-Jones P (1990) Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer Clin Oncol 26(4):463–469CrossRef
  12.Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17(1):409PubMed
  13.Belani CP, Barstis J, Perry MC et al (2003) Multicenter, randomized trial for stage IIIb or IV non–small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21(15):2933–2939CrossRef PubMed
  14.van Hagen P, Hulshof MCCM, van Lanschot JJB et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084CrossRef PubMed
  15.Agarwala S, Cano E, Heron D et al (2007) Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Ann Oncol 18(7):1224–1229CrossRef PubMed
  16.CfCCM-A Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26(35):5802–5812CrossRef
  17.Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD (1990) Carboplatin in childhood brain tumors: a children’s cancer study group phase II trial. Cancer 66(12):2465–2469CrossRef PubMed
  18.Kortmann RD, Kühl J, Timmermann B (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the german prospective randomized trial hit’91. Int J Radiat Oncol Biol Phys 46(2):269–279CrossRef PubMed
  19.Zeltzer PM, Boyett JM, Finlay JL et al (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the children’s cancer group 921 randomized phase III study. J Clin Oncol 17(3):832–832PubMed
  20.Patel M, McCully C, Godwin K, Balis F (2003) Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61(3):203–207CrossRef PubMed
  21.Stupp R, Gander M, Leyvraz S, Newlands E (2001) Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2(9):552–560CrossRef PubMed
  22.Batchelor T (2000) Temozolomide for malignant brain tumours. Lancet 355(9210):1115–1116CrossRef PubMed
  23.Nifterik KA, Berg J, Stalpers LJA (2007) Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 69(4):1246–1253CrossRef PubMed
  24.Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5 year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466CrossRef PubMed
  25.Loh KC, Willert J, Meltzer H et al (2005) Temozolomide and radiation for aggressive pediatric central nervous system malignancies. J Pediatr Hematol Oncol 27(5):254–258CrossRef PubMed
  26.Terasaki M, Bouffet E, Maeda M, Sugita Y, Sawamura Y, Morioka M (2012) Successful treatment of leptomeningeal gliomatosis of pilomyxoid astrocytoma after failed frontline chemotherapy. Neurologist 18(1):32–35CrossRef PubMed
  27.Yamasaki K, Yokogami K, Ohta H et al (2014) A case of primary diffuse leptomeningeal gliomatosis. Brain Tumor Pathol 31(3):177–181CrossRef PubMed
  28.Malbari F, Atlas M (2012) Tolerability of temozolomide in conjunction with craniospinal irradiation for the treatment of pediatric CNS embryonal tumours. Neuro Oncol 14:i82–i105CrossRef
  29.Müller K, Schlamann A, Guckenberger M et al (2014) Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. Strahlenther Onkol 190(4):377–381CrossRef PubMed
  30.Müller K, Schlamann A, Seidel C et al (2013) Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma. Strahlenther Onkol 189(8):693–696CrossRef PubMed
  31.Taylor RE, Bailey CC, Robinson K et al (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 study. J Clin Oncol 21(8):1581–1591CrossRef PubMed
  32.Xianyuan Song RAA, Dunn ST, Kar-ming Fung, Farmer P, Gandhi S, Ranjan T, Demopoulos A, Symons M, Schulder M, Jian LY (2011) Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. Int J Clin Exp Pathol 47:651–660
  33.Ali S, Joseph N, Perry A, Barajas R Jr, Cha S (2014) Apparent diffusion coefficient in glioblastoma with PNET-like components, a GBM variant. J Neurooncol 119(2):353–360CrossRef PubMed
  34.Stark AM, Nabavi A, Mehdorn HM, Blömer U (2005) Glioblastoma multiforme—report of 267 cases treated at a single institution. Surg Neurol 63(2):162–169CrossRef PubMed
  35.Krex D, Klink B, Hartmann C et al (2007) Long-term survival with glioblastoma multiforme. Brain 130(10):2596–2606CrossRef PubMed
  
• 作者单位：Ben O’Leary (1) (2)
  Henry C. Mandeville (1)
  Naomi Fersht (3)
  Francesca Solda (3)
  Julie Mycroft (1)
  Stergios Zacharoulis (1)
  Sucheta Vaidya (1)
  Frank Saran (1)
  
  1. The Royal Marsden Hospital NHS Trust, The Royal Marsden Hospital, Fulham Rd, London, SW3 6JJ, UK
  2. The Institute of Cancer Research, 237 Fulham Rd, London, SW3 6JB, UK
  3. Department of Oncology, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London, NW1 2PG, UK
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  
• 出版者：Springer Netherlands
• ISSN：1573-7373

文摘

There is no standard treatment for glioblastoma with elements of PNET (GBM-PNET). Conventional treatment for glioblastoma is surgery followed by focal radiotherapy with concurrent temozolomide. Given the increased propensity for neuroaxial metastases seen with GBM-PNETs, craniospinal irradiation (CSI) with temozolomide (TMZ) could be a feasible treatment option but little is known regarding its toxicity. The clinical records of all patients treated at two UK neuro-oncology centres with concurrent CSI and TMZ were examined for details of surgery, radiotherapy, chemotherapy and toxicities related to the CSI-TMZ component of their treatment. Eight patients were treated with CSI-TMZ, the majority (6/8) for GBM-PNET. All patients completed radiotherapy to the craniospinal axis 35–40 Gy in 20–24 daily fractions with a focal boost to the tumour of 14–23.4 Gy in 8–13 daily fractions. Concurrent TMZ was administered at 75 mg/m2 for seven of the cohort, with the other patient receiving 50 mg/m2. The most commonly observed non-haematological toxicities were nausea and vomiting, with all patients experiencing at least grade 2 symptoms of either or both. All patients had at least grade 3 lymphopaenia. Two patients experience grade 4 neutropaenia and grade 3 thrombocytopaenia. Three of the eight patients required omission of TMZ for part of their chemoradiotherapy and 3/8 required hospital admission at some point during chemoradiotherapy. The addition of TMZ to CSI did not interrupt radiotherapy. Principal toxicities were neutropaenia, lymphopaenia, thrombocytopaenia, nausea and vomiting. Treatment with CSI-TMZ merits further investigation and may be suitable for patients with tumours at high-risk of metastatic spread throughout the CNS who have TMZ-sensitive pathologies.